Sana Biotechnology, Inc.
SANA
$2.81
$0.2911.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.41% | -16.87% | -26.75% | -0.75% | -2.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.71% | -32.78% | 1.26% | -52.22% | 34.03% |
| Operating Income | 53.71% | 32.78% | -1.26% | 52.22% | -34.03% |
| Income Before Tax | 54.05% | 44.31% | -6,189.84% | 55.88% | -30.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.05% | 44.31% | -6,189.84% | 55.88% | -30.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.05% | 44.31% | -6,189.84% | 55.88% | -30.87% |
| EBIT | 53.71% | 32.78% | -1.26% | 52.22% | -34.03% |
| EBITDA | 55.59% | 34.08% | -2.15% | 53.90% | -36.83% |
| EPS Basic | 57.97% | 53.49% | -5,190.00% | 63.77% | -15.16% |
| Normalized Basic EPS | 57.43% | 49.05% | 13.25% | 59.22% | -17.16% |
| EPS Diluted | 57.97% | 53.45% | -5,293.88% | 63.77% | -15.16% |
| Normalized Diluted EPS | 57.43% | 49.05% | 11.75% | 59.22% | -17.16% |
| Average Basic Shares Outstanding | 9.34% | 19.76% | 19.51% | 21.76% | 13.63% |
| Average Diluted Shares Outstanding | 9.34% | 19.76% | 17.43% | 21.76% | 13.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |